» Articles » PMID: 35055399

Plasma Levels of Mid-Regional Proadrenomedullin Accurately Identify H1N1pdm09 Influenza Virus Patients with Risk of Intensive Care Admission and Mortality in the Emergency Department

Abstract

Early identification of severe viral pneumonia in influenza virus A (H1N1pdm09) patients is extremely important for prompt admission to the ICU. The objective is to evaluate the usefulness of MR-proadrenomedullin (MR-proADM) compared to C reactive protein (CRP), procalcitonin (PCT), and ferritin in the prognosis of influenza A pneumonia. This prospective, observational, multicenter study included one hundred thirteen patients with confirmed influenza virus A (H1N1pdm09) admitted to an Emergency Department and ICUs of six hospitals in Spain. Measurements and Main Results: one-hundred thirteen patients with confirmed influenza virus A (H1N1pdm09) were enrolled. Seventy-five subjects (mortality 29.3%) with severe pneumonia caused by influenza A H1N1pdm09 virus (H1N1vIPN) were compared with 38 controls (CG).The median MR-proADM levels at hospital admission were 1.2 nmol/L (IQR (0.8-2.6) vs. 0.5 nmol/L (IQR 0.2-0.9) in the CG ( = 0.01), and PCT levels were 0.43 μg/L (IQR 0.2-1.2) in the H1N1vIPN group and 0.1 μg/L (IQR 0.1-0.2) in the CG ( < 0.01). CRP levels at admission were 15.5 mg/dL(IQR 9.2-24.9) in H1N1vIPN and 8.6 mg/dL(IQR 3-17.3) in the CG ( < 0.01). Ferritin levels at admission were 558.1 ng/mL(IQR 180-1880) in H1N1vIPN and 167.7 ng/mL(IQR 34.8-292.9) in the CG ( < 0.01). A breakpoint for hospital admission of MR-proADM of 1.1 nmol/L showed a sensitivity of 55% and a specificity of 90% (AUC-ROC0.822). Non-survivors showed higher MR-proADM levels: median of 2.5 nmol/L vs. 0.9 nmol/L among survivors ( < 0.01). PCT, CRP, and ferritin levels also showed significant differences in predicting mortality. The MR-proADM AUC-ROC for mortality was 0.853 ( < 0.01). In a Cox proportional hazards model, MR-proADM levels > 1.2 nmol/L at hospital admission were significant predictive factors for ICU and 90-day mortality (HR: 1.3). Conclusions: the initial MR-proADM, ferritin, CRP, and PCT levels effectively determine adverse outcomes and risk of ICU admission and mortality in patients with influenza virus pneumonia. MR-proADM has the highest potency for survival prediction.

Citing Articles

Adrenomedullin as a New Prosperous Biomarker in Infections: Current and Future Perspectives.

Trojan G, Moniuszko-Malinowska A, Grzeszczuk A, Czupryna P J Clin Med. 2024; 13(20).

PMID: 39458091 PMC: 11508582. DOI: 10.3390/jcm13206142.


A Focus on the Pathophysiology of Adrenomedullin Expression: Endothelitis and Organ Damage in Severe Viral and Bacterial Infections.

Spoto S, Basili S, Cangemi R, Yuste J, Lucena F, Romiti G Cells. 2024; 13(11.

PMID: 38891025 PMC: 11172186. DOI: 10.3390/cells13110892.


Latest developments in early diagnosis and specific treatment of severe influenza infection.

Valenzuela-Sanchez F, Valenzuela-Mendez B, Rodriguez-Gutierrez J, Estella A J Intensive Med. 2024; 4(2):160-174.

PMID: 38681787 PMC: 11043645. DOI: 10.1016/j.jointm.2023.09.006.


Circulating mid-regional proadrenomedullin is a predictor of mortality in patients with COVID-19: a systematic review and meta-analysis.

Wang N, Liu L, He W, Shang N, Li J, Qin Z BMC Infect Dis. 2023; 23(1):305.

PMID: 37158819 PMC: 10165584. DOI: 10.1186/s12879-023-08275-z.


The Role of Biomarkers in Influenza and COVID-19 Community-Acquired Pneumonia in Adults.

Carbonell R, Moreno G, Martin-Loeches I, Bodi M, Rodriguez A Antibiotics (Basel). 2023; 12(1).

PMID: 36671362 PMC: 9854478. DOI: 10.3390/antibiotics12010161.


References
1.
Cuquemelle E, Soulis F, Villers D, Roche-Campo F, Ara Somohano C, Fartoukh M . Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre study. Intensive Care Med. 2011; 37(5):796-800. PMC: 7080069. DOI: 10.1007/s00134-011-2189-1. View

2.
Perez-Carrasco M, Lagunes L, Anton A, Gattarello S, Laborda C, Pumarola T . Influenza infection in the intensive care unit: Four years after the 2009 pandemic. Enferm Infecc Microbiol Clin. 2015; 34(3):177-83. DOI: 10.1016/j.eimc.2015.04.004. View

3.
Ingram P, Inglis T, Moxon D, Speers D . Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection. Intensive Care Med. 2010; 36(3):528-32. PMC: 7080172. DOI: 10.1007/s00134-009-1746-3. View

4.
Zaninotto M, Mion M, Marchioro L, Padoan A, Plebani M . Endothelial dysfunction and Mid-Regional proAdrenomedullin: What role in SARS-CoV-2 infected Patients?. Clin Chim Acta. 2021; 523:185-190. PMC: 8452353. DOI: 10.1016/j.cca.2021.09.016. View

5.
Saeed K, Wilson D, Bloos F, Schuetz P, van der Does Y, Melander O . Correction to: The early identification of disease progression in patients with suspected infection presenting to the emergency department: a multi-centre derivation and validation study. Crit Care. 2019; 23(1):255. PMC: 6628495. DOI: 10.1186/s13054-019-2536-0. View